A 7-Week, Randomized, Double-Blind Trial of Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) for treatment of acute bipolar I depression compared with lamotrigine. METHOD: The 7-week, acute phase of a randomized, double-blind study compared OFC (6/25, 6/50, 12/25, or 12/50 mg/day; N = 205) with lamotrigine ([LMG] titrated to 200 mg/day; N = 205) in patients with DSM-IV-diagnosed bipolar I disorder, depressed. The study was conducted from November 2003 to August 2004. RESULTS: Completion rates were similar between treatments (OFC, 66.8% vs. LMG, 65.4%; p = .835). OFC-treated patients had significantly greater improvement than lamotrigine-treated patients in change from baseline across the 7-week treatment period on the Clinical Global Impressions-Severity of Illness scale (primary outcome) (p = .002, effect size = 0.26), Montgomery-Asberg Depression Rating Scale (MADRS) (p = .002, effect size = 0.24), and Young Mania Rating Scale total scores (p = .001, effect size = 0.24). Response rates did not significantly differ between groups when defined as > or = 50% reduction in MADRS score (OFC, 68.8% vs. LMG, 59.7%; p = .073). Time to response was significantly shorter for OFC-treated patients (median days [95% CI] = OFC, 17 [14 to 22] vs. LMG, 23 [21 to 34]; p = .010). There was a significant difference in incidence of "suicidal and self-injurious behavior" adverse events (OFC, 0.5% vs. LMG, 3.4%; p = .037). Somnolence, increased appetite, dry mouth, sedation, weight gain, and tremor occurred more frequently (p < .05) in OFC-treated patients than lamotrigine-treated patients. Weight, total cholesterol, and triglyceride levels were significantly elevated in OFC-treated patients compared with lamotrigine-treated patients (all p < or = .001). CONCLUSIONS: Patients with acute bipolar I depression had statistically significantly greater improvement in depressive and manic symptoms, more treatment-emergent adverse events, greater weight gain, and some elevated metabolic factors with OFC than lamotrigine. Treatment differences were of modest size.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Olanzapine‐fluoxetine combination (level 2)264, 265 is effective and is also recommended as a second‐line option.”
Citations
Cites
Still being checked.
Cited by
Items 201–239 of 239
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0001
Baldwin, A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.003.0014
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0009
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0012
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0014
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0010
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0007
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0013
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0005
Goumalatsou, C. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0002
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.003.0011
Denniston, A. K., & Mathewson, P. A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0004
Hjelde, N. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0011
Graham, B. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.003.0009
Kloiber, S. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_46
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0004
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0010
JABC, & JML (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0008
Baldwin, A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0007
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0002
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0003
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780198827191.002.0011
Reference intervals—biochemistry
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.002.0012
Reference intervals—haematology
(2020) · Oxford University Press eBooks · doi:10.1093/med/9780192888501.002.0013
Medications for Bipolar Disorder
Mitchell, P. B. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_135-1
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd05
Medications for Bipolar Disorder
Mitchell, P. B. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_135 · Cited by 1
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg002.pub2
Sharma, S., Singh, N. R., & Bala, N. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20253377
Azim, L., Al-Ashmori, S., Butcher, C., Cipriani, A., Chew-Graham, C. A., Clare, E., Clark, E., Cole, M., Carella, S., Dixon, L., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-112677
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0005
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0010
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0008
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0015
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0003
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0002
JABC, & JML (2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0006
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0011
(2016) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0012
Metadata
- Authors
- Brown, E. B., McElroy, S. L., Keck, P. E., Deldar, A., Adams, D. H., Tohen, M., & Williamson, D. J.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-07-15
- Volume
- 67
- Issue
- 07
- Pages
- 1025-1033
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2011797837
- Cited by
- 244
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 32 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 32 · 2015: 9 · 2014: 15 · 2013: 11 · 2012: 10
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- bipolar I depression, olanzapine-fluoxetine combination, lamotrigine, atypical antipsychotics, antidepressant efficacy, treatment response time, adverse events, weight gain, tolerability, mood stabilizers, Young Mania Rating Scale, Montgomery-Asberg Depression Rating Scale, clinical global impression
- MeSH terms
- Olanzapine, Lamotrigine, Adult, Anticonvulsants, Benzodiazepines, Bipolar Disorder, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Psychiatric Status Rating Scales, Severity of Illness Index, Antipsychotic Agents, Triazines, Self-Injurious Behavior, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.